<DOC>
	<DOCNO>NCT02670434</DOCNO>
	<brief_summary>The purpose study compare efficacy NK-104-CR Placebo Livalo® reduction LDL-C evaluate safety NK-104-CR patient primary hyperlipidemia mixed dyslipidemia</brief_summary>
	<brief_title>Safety Efficacy Comparison Study NK-104-CR ( Controled Release ) Patients With Primary Hyperlipidemia Mixed Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Male female patient primary hyperlipidemia mixed dyslipidemia ≥18 ≤80 year age time consent ; Fasting plasma LDLC ≥160 mg/dL ≤250 mg/dL TG value ≤300 mg/dL Patients naïve statin able safely discontinue use lipidlowering agent 6 week randomization throughout study participation Homozygous familial hypercholesterolemia ; Any condition may cause secondary dyslipidemia . Newly diagnose poorly control diabetes mellitus define HbA1c &gt; 8 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>